Strongbridge raises $25M in a downsized IPO

Drug developer Strongbridge Biopharma ($SBBP) cleared $25 million in an IPO, bringing in less than a third of the cash it once sought as biotech companies continue to struggle on Wall Street. The company, formerly known as Cortendo, moved 2.5 million shares at $10 each, pricing an offering well below the $86 million it craved last month. Strongbridge is working through Phase III with COR-003, a treatment for Cushing's syndrome, and expects to report data in 2017. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.